• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Pacira BioSciences Inc.

    4/29/25 4:11:36 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCRX alert in real time by email
    DEFA14A 1 tm2428503d4_defa14a.htm DEFA14A

     

    UNITED STATES

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.    )

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
       
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material under §240.14a-12

     

    PACIRA BIOSCIENCES, INC.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)​

     

    Payment of Filing Fee (Check all boxes that apply):

     

    x No fee required
       
    ¨ Fee paid previously with preliminary materials
       
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

    GRAPHIC

    Get informed before you vote *If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number Your Vote Counts! FLASHID-JOB# For complete information and to vote, visit www.ProxyVote.com Control # Ricky Campana P.O. Box 123456 Suite 500 51 Mercedes Way Edgewood, NY 11717 148,294 322,224 1 OF 2 30# Hextone, Inc. P.O. Box 9142 Farmingdale, NY 11735 XXXX XXXX XXXX XXXX PACIRA BIOSCIENCES, INC. 2025 Annual Meeting Vote by June 09, 2025 11:59 PM ET You invested in PACIRA BIOSCIENCES, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 10, 2025. View the Notice & Proxy Statement, Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 27, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote in Person at the Meeting* June 10, 2025 1:30 PM EDT 5 Sylvan Way, Suite 300 Parsippany, NJ 07054 Vote in Person or Virtually at the Meeting: www.cesonlineservices.com/pcrx25_vm

    GRAPHIC

    Voting Items Board Recommends THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com FLASHID-JOB# Control # XXXX XXXX XXXX XXXX 1.00000 322,224 148,294 Under New York Stock Exchange rules, brokers may vote “routine” matters at their discretion if your voting instructions are not communicated to us at least 10 days before the meeting. We will nevertheless follow your instructions, even if the broker’s discretionary vote has already been given, provided your instructions are received prior to the meeting date. PACIRA BIOSCIENCES, INC. 2025 Annual Meeting Vote by June 09, 2025 11:59 PM ET 1. Election of Directors Nominees: 01 Marcelo Bigal 02 Frank D. Lee 03 Alethia Young For 2 Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. For 3 Approval, on an advisory basis, of the compensation of our named executive officers. For 4 Advisory vote to approve the frequency of future advisory votes to approve the compensation of our named executive officers. Year 5 Approval of our Amended and Restated 2011 Stock Incentive Plan. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

    Get the next $PCRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PCRX

    DatePrice TargetRatingAnalyst
    1/30/2025$8.00 → $25.00Sell → Hold
    Truist
    8/13/2024$30.00 → $8.00Buy → Sell
    Truist
    8/12/2024$42.00 → $11.00Overweight → Neutral
    Piper Sandler
    8/12/2024$45.00 → $10.00Overweight → Underweight
    JP Morgan
    8/12/2024Outperform → Mkt Perform
    Raymond James
    8/12/2024$37.00 → $14.00Outperform → Sector Perform
    RBC Capital Mkts
    7/3/2024$38.00 → $25.00Overweight → Equal Weight
    Barclays
    3/7/2024$80.00 → $45.00Overweight
    JP Morgan
    More analyst ratings

    $PCRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

      -- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at the ASGCT Annual Meeting -- BRISBANE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new preliminary data which suggests that clinical immunogenicity does not reduce sustained improvements in knee pain, stiffness and function provided by its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), following loc

      5/15/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

      BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21st at 8:30AM ET.2025 Jefferies Global Healthcare Conference on Wednesday, June 4th at 8:45AM ET. Live audio of the virtual event can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks follo

      5/14/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences Reports First Quarter 2025 Financial Results

      -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2025. First Quarter 2025 Financial Highlights Total revenues of $168.9 millionNet product sales of $136.5 million for EXPAREL, $23.3 million for ZILRETTA, and $5.1 million for iovera°Net income of $4.8 million, or $0.10 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $44.1 million See "Non-GAAP Financial Informa

      5/8/25 4:00:00 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

      SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

      1/19/24 2:40:54 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

      SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

      2/14/23 1:31:32 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

      SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

      1/23/23 3:52:35 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Financials

    Live finance-specific insights

    See more
    • Pacira BioSciences Reports First Quarter 2025 Financial Results

      -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2025. First Quarter 2025 Financial Highlights Total revenues of $168.9 millionNet product sales of $136.5 million for EXPAREL, $23.3 million for ZILRETTA, and $5.1 million for iovera°Net income of $4.8 million, or $0.10 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $44.1 million See "Non-GAAP Financial Informa

      5/8/25 4:00:00 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

      BRISBANE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter financial results after the close of the U.S. markets on Thursday May 8, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the confer

      4/29/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

      — Record revenues of $701 million in 2024 — — Full-year GAAP net loss of $100 million and adjusted EBITDA of $224 million — — Conference call today at 4:30 p.m. ET — PARSIPPANY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2024. "Pacira enters 2025 with a sharp focus on executing our 5x30 strategy to accelerate our transition into an innovative biopharmaceutical organization and therapeutic area leader in musculoskeletal pain and adjacencies," said Frank D. L

      2/27/25 4:05:00 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pacira BioSciences upgraded by Truist with a new price target

      Truist upgraded Pacira BioSciences from Sell to Hold and set a new price target of $25.00 from $8.00 previously

      1/30/25 7:16:40 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences downgraded by Truist with a new price target

      Truist downgraded Pacira BioSciences from Buy to Sell and set a new price target of $8.00 from $30.00 previously

      8/13/24 7:53:59 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Pacira BioSciences from Overweight to Neutral and set a new price target of $11.00 from $42.00 previously

      8/12/24 8:01:11 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Slonin Jonathan was granted 93,600 shares, increasing direct ownership by 100% to 187,044 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      2/4/25 6:26:04 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Administrative Officer Williams Kristen was granted 79,200 shares, increasing direct ownership by 77% to 182,112 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      2/4/25 6:25:54 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Lee Frank D. was granted 350,000 shares, increasing direct ownership by 356% to 448,409 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      2/4/25 6:25:44 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pacira BioSciences Inc.

      10-Q - Pacira BioSciences, Inc. (0001396814) (Filer)

      5/8/25 4:07:07 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Pacira BioSciences, Inc. (0001396814) (Filer)

      5/8/25 4:06:04 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Pacira BioSciences Inc.

      DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)

      4/29/25 4:11:36 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bigal Marcelo bought $20,034 worth of shares (1,512 units at $13.25), increasing direct ownership by 18% to 10,142 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      8/19/24 8:25:55 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Brege Laura bought $12,810 worth of shares (1,000 units at $12.81), increasing direct ownership by 6% to 17,552 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      8/19/24 8:25:46 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Yang Michael J. bought $25,800 worth of shares (2,000 units at $12.90), increasing direct ownership by 38% to 7,230 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      8/14/24 4:35:09 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Pacira Announces Updates to Board of Directors

      -- Accomplished Business and Financial Leader, Laura Brege, Appointed Chair -- -- Paul J. Hastings and Andreas Wicki, PhD Retire from Board of Directors -- PARSIPPANY, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that Laura Brege has been appointed Chair of the Board. Former Chair Paul J. Hastings and Andreas Wicki, PhD. have retired from the Board. These changes align with Pacira's ongoing commitment to Board refreshment. With these changes, the Board is composed of nine directors, eight of whom are independent and

      1/30/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO

      Former CEO, Sander van Deventer to become President of R&D Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package Expansion of corporate footprint into the US (Boston) VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241216441837/en/VectorY strengthens Leadership Team with appointment of Jim Scibetta as new CEO (Photo

      12/16/24 7:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations